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G enomics is growing in just about every way imaginable. Advances in sequencing technology and cloud computing are making genomic analysis more accessible to 
researchers; more and more genomic data is being 
produced; and the political backing is also bringing 
more funding. It is a very exciting time to be 
involved in genomics at any level, but we can’t get 
too excited just yet. 
Managing stakeholder expectations is a constant 
battle. Especially when it comes to ensuring that 
robust and accurate science remain a priority over 
short term goals. Hype is great, in that it shows 
people are excited, but there’s still a long way to go.
FLG: The political arena on both sides of the 
Atlantic has been very vocal about their support and 
backing of Genomics and Precision Medicine in recent 
weeks. Is there a risk in overhyping the public?
GL: Yes, of course. There seems to be an enormous amount 
of hype in the field of human genomics, and we must constantly 
remind people that the path to new drugs and/or the prevention of 
disease can take on the order of decades.
FLG: There’s a sense of a growing disconnect between the 
growing political element and those doing the actual research. Is 
that funding being focused in the right areas of genomic research at 
the moment?
GL: More funding should be directed toward developing more 
accurate and faster sequencing methods, along with engaging 
much more with software engineers and cloud-based computing. 
We have to collectively develop ways to store and share millions 
of genomes going forward, and this is what various scientists and 
members of the Global Alliance for Genomics and Health 
are working on. From my perspective, the emphasis 
should be on further technology development and the 
implementation of highly accurate genome sequencing. 
This is part of what we have been working on in 
collaboration with Michael Schatz and others at Cold 
Spring Harbor Laboratory and elsewhere. Using whole 
genome datasets from 10 members of one family, my 
graduate students, Jason O’Rawe, Han Fang, and Yiyang 
Wu, showed that one can increase the reliability of the 
biological inferences with an integrative bioinformatics 
pipeline, including a new algorithm, Scalpel, developed 
by Giuseppe Narzisi and Michael Schatz, for more 
accurate identification of indels. We find a 2 to 5-fold 
difference in the number of variants detected as being 
relevant for various disease models when using different 
sets of sequencing data and analysis pipelines, and we 
derive greater accuracy when more pipelines are used in 
conjunction with data encompassing a larger portion of 
the family. We also collaborated with Min (Max) He and 
Kai Wang on the development of SeqHBase, a big data-
based toolset for analysing family-based sequencing data, and we 
demonstrated SeqHBase’s high efficiency and scalability on several 
disorders, including a new syndrome, which we are currently 
calling RykDax Syndrome, where we identified a maternally 
inherited missense variant in an X-chromosomal gene, TAF1. A 
“genotype-first” approach led us to other families with variants in 
TAF1 and containing individuals having a remarkably similar clinical 
presentation.
FLG: Genomic technology has, and continues to develop at a 
rapid pace. At the center of this was the race to the ‘$1000 dollar 
genome’. In pursuing faster and cheaper sequencing options, 
accuracy suffered. It has resulted in a drastic growth in the rate at 
which sequencing data is being produced. Was the compromise 
towards speed and affordability worth it? 
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GL: This $1000 dollar genome is still a myth, as you are quite 
correct that such a thing is not accurate. We published papers 
in 2013 and 2014 showing that the accuracy of “whole genome 
sequencing” is far from ideal, and we have recommended that 60x 
coverage is needed to detect >95% of indels, if one uses 100 base 
pair reads from Illumina. This mythical $1000 dollar genome is 
only at 30x coverage and this is the amortized price on the current 
Illumina X10 instrument, which assumes running the instrument 
constantly to churn out 18,000 such genomes per year. I have heard 
of some genome centers charging $1500 for this 30x coverage, 
although the real price is closer to $2,000, I am told, and this does 
not include any of the costs for analysis. Therefore, for a 60x 
coverage Illumina genome, the current cost is $3,000, and even this 
sort of genome still lacks many regions that can only be filled in with 
much longer reads. There is certainly ongoing improvement and 
innovation, including from other sequencing companies, so that 
hopefully in a few years’ time, the accuracy will be much improved. 
However, there is still plenty of work to be done.
FLG: Are people sequencing too much at the moment? It seems 
that every week we see a newly completed genome announced. Is 
this an indication of the potential power of genomics or are we just 
in a period in which sequencing technology is being used simply 
because it has become more accessible?
GL: About four years ago, I started broadly calling for better 
standards in terms of exome sequencing. However, the response 
basically was that implementing better standards makes the cost 
of research too much. So, we find ourselves in the situation of 
having had tens of thousands of exomes sequenced in research 
environments, where the only variants that can be returned to the 
research participants are ones that get Sanger validation (or some 
other validation) in a clinical environment. This was mentioned 
and discussed yet again at the Precision Medicine Workshop held 
recently by the NIH, with various people lamenting the fact that 
there is such a huge divide between the “research” and “clinical” 
worlds, but the response once again concerned mostly cost. So, 
from this perspective, the main work right now should focus on 
getting the cost of sequencing down much further, along with 
getting higher accuracy with longer reads, so that eventually people 
can get their whole genomes sequenced in clinical environments, 
where the chances for sample-swaps and other inaccuracies will 
be less. I do applaud that the FDA has finally approved a direct 
to consumer genetic test for Bloom Syndrome by 23andMe, 
but I certainly hope that the pace and scope of such approvals 
will dramatically increase. We need to get to a world of highly 
accurate and relatively cheap (~$100 genomes), so that it is then 
cost-effective to sequence millions of people, and then collect and 
analyse these data in aggregate to begin to understand how any 
particular genotypes express themselves among many different 
genetic backgrounds. Such things will only be possible with broad 
data sharing, including on the level of phenotype data. One can see 
that this very broad sharing of data, including pictures, is possible, 
as demonstrated by innovative companies like Facebook, 23andMe, 
PatientsLikeMe, and Ancestry.com, although the privacy concerns 
and issues with genetic data are a big issue that must be carefully 
considered. There have also been some recent innovations in face 
recognition and image processing, where one can begin to classify 
genetic syndromes based on photographs.
FLG: In terms of technology coming through today, what do you 
feel is going to make the most useful impact?
GL: The developments going on right now at Pacific Biosciences 
and Oxford Nanopore are very promising in terms of longer reads, 
for sure. Researchers at Cold Spring Harbor Laboratory, including 
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Dick McCombie and Michael Schatz, have been working hard on 
assessing and pushing forward these technologies from Pacific 
Biosciences and Oxford Nanopore, and it seems that we might only 
be a few years away from highly accurate and relatively inexpensive 
human whole genomes. It is also useful that people at the FDA 
seem to be beginning to engage more with how to regulate direct to 
consumer genetic testing in broader fashion. One can also see that 
companies like Google are getting interested in this sector, based 
on their cloud computing capabilities, so one could imagine that this 
could further enable broader data sharing.
FLG: The road to the promised ‘Genomic Revolution’ seems to 
keep stretching out. One of the first major milestones was the 
completion of the Human Genome Project. Back then, President 
Clinton suggested that “our children’s children will know the term 
‘cancer’ as a constellation of stars.” The miracle cures that the public 
were hoping for, never arrived. It was, however, the starting point 
for a lot of great work. Now with large scale sequencing projects 
taking place, it feels like the expectation is that a whole bunch of 
variants are going to be found that we can drug and eradicate 
disease. The reality is that it is very unlikely that a single gene holds 
the answer. So the next step will be to take all of that data and turn 
it into useful information. Is there enough focus on funding the 
kinds of rigorous functional studies that will help deliver something 
tangible to patients?
GL: Although it seems that most people focus on the development 
of drugs to treat illness after it has started, I personally feel that 
large-scale sequencing might actually be more effective in terms 
of early detection and prevention of disease. This remains to be 
proven, of course, but there are early indications that screening 
of family members (known as cascade carrier screening) can 
help to identify other members of the family carrying particular 
mutations and thus at increased risk. Such people can at least 
know about their elevated risk, and there are some instances in 
which people can take action. Perhaps the most famous example 
of this is in women with prominent family histories of breast and 
ovarian cancer, who also carry mutations in the BRCA1 gene. Such 
women can undergo more intensive screenings, or in some cases, 
made famous by Angelina Jolie, elect to undergo interventions 
to reduce their risk, such as with mastectomies. Of course, the 
decision to undergo such a radical intervention particularly when 
the expression of this phenotype is quite variable is something that 
needs to undergo much more study, but on an individual level, 
some people are acting on their genetic information already. 
FLG: You’ve had some experience on the front lines as a clinician 
yourself. Here in the UK, one of the biggest challenges the 100,000 
Genomes Project is trying to address is how to integrate genomics 
into the NHS. This will have to look at work force planning, in 
particular around how to use and support Genetic Counsellors. How 
difficult can it be to introduce something as big as genomics into 
regular clinical practice?
GL: This is indeed an enormous challenge, particularly in the 
United States, where we do not have a national health care system. 
In addition, the number of genetic counsellors in America is on the 
order of only a few thousand, for a population numbering well over 
300 million people. There is also a pressing need to educate health 
care professionals much more about genetics. I am constantly 
reminding people in the genomics world that we live in a tiny bubble 
in comparison to the vast landscape of healthcare in America, and 
we have to prove clinical validity and utility in order to get any sort 
of wider adoption of exome or whole genome sequencing. Such 
things will be enabled by better technology, higher standards, lower 
costs, and broader data sharing. 
FLG: Your research is focused on the genetics of neuropsychiatric 
illnesses at Cold Spring Harbor. What drew you to that particular 
field?
GL: The short answer is that these illnesses are among the 
most fascinating in all of medicine. The long answer concerns the 
broad training that I have had, which requires me to explain my 
background a bit. I conducted some of my training in the Cornell/
Rockefeller/Sloan-Kettering M.D./Ph.D. program. Just prior to 
that, I had spent one year as a Rotary Scholar at the University of 
Cambridge, England, working toward a Master’s degree in Genetics 
at the Wellcome CRC Institute, with Martin Evans as my research 
mentor. By the time I finished my Ph.D. at Rockefeller with Tom 
Muir and Richard Novick and returned to medical school, I had 
been exposed to a variety of research experiences. I had conducted 
research in various laboratories at Dartmouth College, the NIH, the 
University of Cambridge and the Cornell/Rockefeller/Sloan-Kettering 
M.D./Ph.D. program. Some of my research interests had included 
by then: thyroid hormone and its effects on the brain during 
development; cancer research with a focus on chemoprevention; 
the creation and phenotypic characterization of mouse models of 
human disease; the structure and function of proteins, including 
the use of chemistry to synthesize unusual protein variants and 
to analyze complex mixtures; and the development of novel 
anti-infectives for Staphylococcus aureus and other bacterial 
infections. It is safe to say that I had, and continue to have, wide-
ranging interests in biological chemistry, which broadly defined 
encompasses the targeted use of chemistry to elucidate biological 
processes and vice-versa. 
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Upon returning to medical school and rotating through the 
many different clinical rotations, I was struck by the fact that the 
most fascinating and challenging clinical cases for me involved 
illnesses affecting the brain and mind, due mostly to our relative 
lack of knowledge of the complexities of psychiatric and neurologic 
illnesses. I realized that much remains to be discovered and that one 
could fill an entire career focusing on the clinical and basic science 
aspects of diseases like intellectual disability, autism, schizophrenia, 
obsessive-compulsive disorder, Tourette syndrome, or other 
brain-based illnesses. In order to make substantive contributions 
in this area, I felt that I needed extensive clinical exposure to these 
illnesses, so I decided in the year 2003 to pursue clinical residency 
training, first as a psychiatry resident at Columbia and the New 
York State Psychiatric Institute, followed by additional training in 
child and adolescent psychiatry at New York University, Bellevue 
Hospital and Rockland Children’s State Psychiatric Hospital. Upon 
completion of 5 years of clinical training, I started my independent 
career in 2009 in the state of Utah, and I was recruited in 2012 
to establish an active laboratory at Cold Spring Harbor. We focus 
on the discovery of families with rare diseases and/or increased 
prevalence for syndromes such as intellectual disability, autism, 
Tourette syndrome and schizophrenia. Once we identify mutations 
that likely contribute to a disease, we undertake detailed functional 
studies of these mutations and the biological processes affected. 
Proving the biological relevance for newly discovered mutations is 
the major problem, so having access to research participants and 
derived tissues is critically important, hence the need to engage 
directly with families.
FLG: You split your time as a researcher at the Utah Foundation 
for Biomedical Research (UFBR) as well. What kind of projects are 
you working on at the moment?
GL: We study the breadth and depth of genetic variants in Utah, 
where there is a large founding population, large family structures 
and good genealogical records, which enables well powered 
family-based genetic studies for rare diseases. We use exome 
and whole genome sequencing (WGS) to identify mutations that 
segregate with various idiopathic syndromes, and we undertake 
comprehensive functional studies of many of the newly identified 
mutations. This has led to the discovery of many new genetic 
syndromes, including Ogden Syndrome, RBCK1 Syndrome, and 
most recently RykDax Syndrome. This latter syndrome presents 
with severe intellectual disability (ID), a characteristic intergluteal 
crease, and very distinctive facial features. We continue to 
advocate for more comprehensive and accurate whole genome 
analyses in large pedigrees, and we have collected ~2000 DNA 
samples to date from >100 families in Utah, including detailed 
phenotyping information. Some of these samples have undergone 
exome or whole genome sequencing, and we are currently 
analyzing these data. This includes the ongoing analysis of whole 
genomes from 3 families with singleton cases of autism, and an 
analysis of nine whole genomes from a pedigree with Prader–
Willi Syndrome (PWS), Hereditary Hemochromatosis, Familial 
Dysautonomia (FD), and Tourette Syndrome.
FLG: We interviewed Michael Vellard, from Ultragenyx last 
December. He had family reasons for wanting to develop treatments 
for rare diseases, and was very passionate about the potential 
relevance of his research to other, more common, indications. What 
attracted you to start researching into rare diseases?
GL: When I finished my M.D.-Ph.D. training in 2004, I was 
full of ideas about what research I might do in my future 
academic career. However, I decided to broaden my training by 
undertaking the clinical residency. Now, many years later, I am 
so glad that I undertook clinical training, as my eyes are now 
fully open to the complexity and nuance of the human condition, 
which cannot possibly be understood fully by studying the 
outcome of mutations only in mice or other lower animal models. 
Due mostly to my clinical training, my outlook has broadened to 
include a focus on rare diseases with very strong phenotypes, 
as these provide a window into very interesting and important 
biology. I believe that my background in genetics, chemistry, 
pharmacology, and medicine allows me to interface with basic 
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scientists and clinicians in the discovery and 
characterization of new genetic syndromes. It is 
critical for suitably trained physician-scientists or 
other broadly trained individuals to be involved 
with careful phenotyping and collection of human 
pedigrees with particular disorders, followed by 
a well-thought out experimental design in terms 
of whole genome sequencing and follow-up 
experiments. 
FLG: Going back to the NIH Precision Medicine 
Workshop, do you think more people should try 
get a broad experience across research and clinical 
practice to try eliminate the present divide between 
the two?
GL: Yes, definitely. There is a major dearth of 
physician-scientists and other broadly trained 
scientists right now in America, and there is also a 
hyper-specialization that has occurred partly due to 
the way that NIH funding is determined, including 
evaluation of research grants by hyper-specialized 
study sections. I have been constantly amazed that there is very little 
reward in the current system for people with broad, interdisciplinary 
training, and in fact, I have received grant evaluations somehow 
lamenting the fact that I am not “focused enough” on one particular 
topic. I have heard that the NIH is trying to figure out ways to 
support broadly trained individuals, and I would certainly support 
such efforts. We definitely need to figure out ways to bridge this 
substantial divide between research and clinical practice, and this 
can only be done with the aid of people trained in both areas. I have 
been incredibly lucky at Cold Spring Harbor Laboratory that the 
president, Bruce Stillman, and the chancellor emeritus, Jim Watson, 
have been so supportive of my work.
FLG: As genomics develops as a field over the next 15-20 years, 
what would you like to have achieved through your work?
GL: I have been advocating for more rigorous standards regarding 
the collection of human genetic data, including with the accuracy of 
variant calls. Instead of compartmentalizing research and medicine, 
the two should be integrated so that physicians who are most 
familiar with human “phenotypes,” can inform the other arms of 
science. This is certainly beginning to happen, and I am very much 
helping to push this forward.
FLG: For students at the start of a potential career in genomic 
research, would you have any advice or recommendations about 
how they should look to develop their areas of focus?
GL: Get a broad training! For me, science is all about trying to 
understand biology using whatever tools I can bring to the table. 
Therefore, genomics is just one of many tools out there. Over the 
course of my career, I have used many other tools, including cell 
culture, genome-edited mice, peptide chemistry, protein expression, 
mass spectrometry, and yeast genetics. So, I tend to pick biological 
questions and then figure out the best tools and techniques that I 
might need to answer the questions.
FLG: Since you joined Twitter in 2011, you have been steadily 
developing an impressive following. It seems that twitter is the 
social media platform of choice for a lot of 
researchers at the moment. As a frequent 
tweeter, you give a lot to the community. What’s 
your main motivation for maintaining your 
online presence? Have you had anything out of 
the ordinary happen to you online yet?
GL: I use Twitter as a way to communicate with 
other scientists and the general public. It is a great 
way to keep up to date on what is happening in 
science in general, along with also seeing how the 
blogosphere reacts to overly hyped papers. Most 
people do not want to take the time to criticize 
papers, either at all or in various snail-mail venues 
such as “letters to the editor”, whereas a few 
scientists are at least willing to send out a tweet 
or post something on a blog to call out various 
papers. I do think that such analyses help to alert 
people regarding recidivist behaviours on the 
part of some scientists who tend to overly hype 
their results. This is particularly prominent for 
some people who tend to issue overly dramatic 
(and sometimes misleading) press releases about their work. These 
things take time, but it is my hope that the younger generation of 
scientists will learn from such things on Twitter that it is actually 
damaging to your career and reputation to engage in so much hype 
and spin. People may or may not directly call out such behaviour 
publicly, but they certainly talk about these things at meetings 
and in other venues, and a poor reputation ultimately leads to 
less funding and support for your work. In regards to your other 
question, luckily, I have had mostly positive interactions on Twitter 
to date.
FLG: Is there anything else you would like to mention to our 
readers?
GL: The incentive structure in academic science is really skewed 
in favour of publications. This results in the churning out of many 
substandard papers, all due to the fact that each person has 
traditionally been held to the standard that they must be first 
or last author on some decent number of publications in order 
to be considered for certain grant monies. This dis-incentivizes 
collaboration, and I have personally witnessed behaviours 
involving withholding genetic data and pedigrees due to the 
fact that some group demands that they absolutely must be 
the sole first and/or last author on some paper. I have tried to 
counteract such behaviour by contributing to and helping to 
promote the BioRxiv preprint server, which was started by Cold 
Spring Harbor Laboratory Press as a way to encourage the open 
sharing of results. I am also on the editorial board of a new journal 
from CSHL Press, called Molecular Case Studies, which aims to 
present genomic and molecular analyses of individuals or cohorts 
alongside their clinical presentations and phenotypic information. 
The plan is to have a rapid peer-review process that is based on 
technical evaluation of the analyses performed, not the novelty of 
findings, and offers a swift, clear path to publication.
FLG: Thank you very much for your time, and good luck with your 
research!
GL: Thank you! ■
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